Clinical Trial Search

Primary: Safety: Number of Participants With Freedom From Device and Procedure-related Major Adverse Events — 18 Participants — p=0.1309

Primary: Issues Related to Type of Neutropenia Management That Are Most Important to Children and Their Caregivers. — 3 key themes identified

Primary: Overall Survival in Participants That Received Quizartinib Versus Salvage Chemotherapy — 27.0; 20.4 weeks — p=0.0185

Primary: Trough Forced Expiratoty Volume in 1 Second (FEV1) — 0.171; 0.212 L

Primary: Percentage of Participants With Treatment Success at Week 8 — 38.41; 11.99 percentage of participants

Primary: Number of Responders Measured by Clinical Global Impression (CGI) — 5 Participants

Primary: Number of Participants Pregnant After 4 Weeks — 85; 82 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 4; 2; 4; 3 Participants

Primary: HIV Knowledge — 11.10; 10.98 score on a scale

Primary: Change in Hamilton Depression Rating Scale HDRS-21 — 5.5; 2.8 score on a scale — p=<0.05

Primary: Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified…

Primary: Absolute Change From Baseline in HDL-C — 12.76; 0.50 mg/dL

Primary: Objective Response Rate (ORR) — 0; 5; 16; 8 Participants

Primary: Phase 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 6; 6; 3; 3 Participants

Primary: Glucose Uptake — 0; 8 change in glucose infusion rate (ml/hr)